These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 28315807

  • 1. Association of CYP2C9, CYP2A6, ACSM2A, and CPT1A gene polymorphisms with adverse effects of valproic acid in Chinese patients with epilepsy.
    Wang C, Wang P, Yang LP, Pan J, Yang X, Ma HY.
    Epilepsy Res; 2017 May; 132():64-69. PubMed ID: 28315807
    [Abstract] [Full Text] [Related]

  • 2. Associations of CYP2C9 and CYP2A6 Polymorphisms with the Concentrations of Valproate and its Hepatotoxin Metabolites and Valproate-Induced Hepatotoxicity.
    Zhao M, Zhang T, Li G, Qiu F, Sun Y, Zhao L.
    Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):138-143. PubMed ID: 28273397
    [Abstract] [Full Text] [Related]

  • 3. Influence of CYP2C9 and CYP2A6 on plasma concentrations of valproic acid: a meta-analysis.
    Yoon HY, Ahn MH, Yee J, Lee N, Han JM, Gwak HS.
    Eur J Clin Pharmacol; 2020 Aug; 76(8):1053-1058. PubMed ID: 32385545
    [Abstract] [Full Text] [Related]

  • 4. Factors Influencing Plasma Concentrations of Valproic Acid in Pediatric Patients With Epilepsy and the Clinical Significance of CYP2C9 Genotypes in Personalized Valproic Acid Therapy.
    Ma B, Yang K, Li X, Su N, Yu T, Zou Y, Xu X, Wang F, Cheng J, Yan Z, Chen T, Zhang L.
    Ther Drug Monit; 2024 Aug 01; 46(4):503-511. PubMed ID: 38287884
    [Abstract] [Full Text] [Related]

  • 5. Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy.
    Zhu X, Li X, Zhang T, Zhao L.
    Basic Clin Pharmacol Toxicol; 2018 Nov 01; 123(5):628-634. PubMed ID: 29791065
    [Abstract] [Full Text] [Related]

  • 6. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients.
    Tan L, Yu JT, Sun YP, Ou JR, Song JH, Yu Y.
    Clin Neurol Neurosurg; 2010 May 01; 112(4):320-3. PubMed ID: 20089352
    [Abstract] [Full Text] [Related]

  • 7. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype.
    Kiang TK, Ho PC, Anari MR, Tong V, Abbott FS, Chang TK.
    Toxicol Sci; 2006 Dec 01; 94(2):261-71. PubMed ID: 16945988
    [Abstract] [Full Text] [Related]

  • 8. Association of valproic acid and 2-propyl-4-pentenoic acid concentrations with adverse reaction in 254 Chinese patients with epilepsy.
    Ma H, Zhu W, Wang C, Pan J, Yang X, Luo J, Wang P.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2019 Jul 28; 44(7):775-783. PubMed ID: 31413215
    [Abstract] [Full Text] [Related]

  • 9. Impact of CYP2C19 and CYP2C9 gene polymorphisms on sodium valproate plasma concentration in patients with epilepsy.
    Song C, Li X, Mao P, Song W, Liu L, Zhang Y.
    Eur J Hosp Pharm; 2022 Jul 28; 29(4):198-201. PubMed ID: 32868386
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical significance of CYP2C9-status guided valproic acid therapy in children.
    Bűdi T, Tóth K, Nagy A, Szever Z, Kiss Á, Temesvári M, Háfra E, Garami M, Tapodi A, Monostory K.
    Epilepsia; 2015 Jun 28; 56(6):849-55. PubMed ID: 25967074
    [Abstract] [Full Text] [Related]

  • 12. Effects of UGT1A, CYP2C9/19 and ABAT polymorphisms on plasma concentration of valproic acid in Chinese epilepsy patients.
    Zheng XX, You YX, Zhao LL, Du Y, Xu SQ, Tang DQ.
    Pharmacogenomics; 2023 Feb 28; 24(3):153-162. PubMed ID: 36718958
    [Abstract] [Full Text] [Related]

  • 13. Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy.
    Guo Y, Hu C, He X, Qiu F, Zhao L.
    Drug Metab Pharmacokinet; 2012 Feb 28; 27(5):536-42. PubMed ID: 23099353
    [Abstract] [Full Text] [Related]

  • 14. Influence of uridine diphosphate glucuronosyltransferase 2B7 -161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients.
    Inoue K, Suzuki E, Yazawa R, Yamamoto Y, Takahashi T, Takahashi Y, Imai K, Koyama S, Inoue Y, Tsuji D, Hayashi H, Itoh K.
    Ther Drug Monit; 2014 Jun 28; 36(3):406-9. PubMed ID: 24365988
    [Abstract] [Full Text] [Related]

  • 15. Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients.
    Amini-Shirazi N, Ghahremani MH, Ahmadkhaniha R, Mandegary A, Dadgar A, Abdollahi M, Shadnia S, Pakdaman H, Kebriaeezadeh A.
    Toxicol Mech Methods; 2010 Oct 28; 20(8):452-7. PubMed ID: 20602621
    [Abstract] [Full Text] [Related]

  • 16. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid.
    Sadeque AJ, Fisher MB, Korzekwa KR, Gonzalez FJ, Rettie AE.
    J Pharmacol Exp Ther; 1997 Nov 28; 283(2):698-703. PubMed ID: 9353388
    [Abstract] [Full Text] [Related]

  • 17. Catalase C-262T Polymorphism Is a Risk Factor for Valproic Acid-Induced Abnormal Liver Function in Chinese Patients With Epilepsy.
    Ma L, Pan Y, Sun M, Shen H, Zhao L, Guo Y.
    Ther Drug Monit; 2019 Feb 28; 41(1):91-96. PubMed ID: 30422963
    [Abstract] [Full Text] [Related]

  • 18. Simultaneous determination of valproic acid and 2-propyl-4-pentenoic acid for the prediction of clinical adverse effects in Chinese patients with epilepsy.
    Chen ZJ, Wang XD, Wang HS, Chen SD, Zhou LM, Li JL, Shu WY, Zhou JQ, Fang ZY, Zhang Y, Huang M.
    Seizure; 2012 Mar 28; 21(2):110-7. PubMed ID: 22055352
    [Abstract] [Full Text] [Related]

  • 19. Effect of Ginkgo biloba extract on oxidative metabolism of valproic acid in hepatic microsomes from donors with the CYP2C9*1/*1 genotype.
    Numa AM, Abbott FS, Chang TK.
    Can J Physiol Pharmacol; 2007 Sep 28; 85(9):848-55. PubMed ID: 18066130
    [Abstract] [Full Text] [Related]

  • 20. Impact of CYP2C9*2 and *3 polymorphisms on valproate-associated adverse drug reactions in individuals living with epilepsy: a case-control study.
    Ramakrishnan K, Kesavan R, Venkatraman S, Narayan SK, Kumar RR, Shewade D.
    Per Med; 2023 Sep 28; 20(5):417-424. PubMed ID: 37811569
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.